EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 138 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR COVID-19 Vaccine Myth Busters January 28, 2021 Teacher Battling Cancer Gifted Free School Supplies August 25, 2021 FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer July 8, 2020 Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... September 7, 2022 Load more HOT NEWS Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer What Are Biosimilars in Cancer Treatment? Cancer Rehabilitation Starts at Diagnosis: Part II 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During...
